Since 2002, Hugo the Cate is professor of Clinical Thrombosis and Hemostasis at the Cardiovascular Research Institute (CARIM), University Medical Center Maastricht. He previously worked at the University of Amsterdam and as a researcher at Harvard Medical School. Nationally and internationally, he is one of the most productive and successful scientists in the field of Hemostaseology, which is shown in more than 200 articles published in leading journals. In Mainz, he will establish a research group and continue his experimental and translational studies with colleagues and young scientists of the CTH.
Since 2003 Rupert Bauersachs is head of the Department of Vascular Medicine at the Klinikum Darmstadt GmbH, and he is founding member of the Interdisciplinary Vascular Center. He also is Professor of Internal Medicine and Vascular Medicine at the Goethe University in Frankfurt, where he was acting director of the Department of Vascular Medicine from 1999 to 2003. Professor Bauersachs is board certified for Vascular Medicine, Internal Medicine, Haemostaseology, Phlebology and Diabetology. His broad scientific and clinical focus includes the development of new antithrombotic agents for the treatment of thromboembolic disorders, thrombophilia, heparin-induced thrombocytopenia, ischemia and reperfusion. One of his main concerns and interests is the improvement of the care of specific, vulnerable patient groups that are commonly neglected in large clinical trials, for example elderly, frail patients, patients with impaired renal function, patients with cancer or pregnant women. His professorship thus focuses on Vulnerable Individuals and Populations in Thrombosis and Hemostasis (VIP-TH). Professor Bauersachs has conducted the largest prospective trial in pregnant women at increased risk for venous thromboembolism, the EThIG-Study. This study, enrolling more than 800 high-risk pregnant women, showed that a risk-stratified administration of low molecular weight heparin is both safe and effective in pregnancy. With the interdisciplinary infrastructure available at the CTH and the translational research program, detailed analyses and follow-up studies are possible to further improve the management and outcome of pregnant women with venous thromboembolism.
Dr. Stepan Gambaryan is currently Professor of Cytology and Histology, Biological faculty, of S. Petersburg State University (Russia) and Scientist at the Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, S. Petersburg, Russia. Previously, he worked for 20 years with Dr. Suzanne Lohmann and Professor Ulrich Walter as invited research scientist of the SFB 355 “Heart failure” (1993-2014) and SFB688 “Cardiovascular cell-cell interactions” (2006-2013) at the Institute of Clinical Biochemistry and Pathobiochemistry, University of Wurzburg, Germany. His main areas of research are the mechanisms of action of NO, cGMP, cAMP and their interactions with other intracellular pathways in cardiovascular cells. He has published more than 100 articles in this area. As Guest Scientist in Mainz since September 2015, Dr. Gambaryan joined the team of PD Dr. Kerstin Jurk and Prof. Ulrich Walter to study the interaction of platelet stimulatory and inhibitory pathways at the level of phosphoproteomics. In particular, the interaction of important platelet adhesion receptors and cAMP/cGMP signaling will be studied.